Shattuck Labs Earnings Call Transcripts
Fiscal Year 2026
-
A novel DR3 blocking antibody program aims to overcome immunogenicity and efficacy limitations of TL1A blockers in IBD. Phase I data for SL-325 will be released in Q2, with a phase IIb Crohn's trial starting in Q3. Bispecifics and lifecycle management strategies are also advancing.
Fiscal Year 2025
-
Targeting the TL1A receptor may offer superior safety and efficacy over ligand-blocking due to reduced immunogenicity and stable receptor expression. Phase 1 data in healthy volunteers support a differentiated profile, with rapid advancement to phase 2 and combination strategies planned.
-
SL-325, a DR3 blocking antibody, aims to offer more durable and safer inhibition of the TL1A/DR3 axis in inflammatory diseases compared to TL1A blockers. Phase I data will be shared in early 2026, with phase II trials and funding secured through 2029.
-
DR3 is a stable, broadly expressed target in IBD, offering potential efficacy and safety advantages over TL1A blockade. SL-325, a high-affinity DR3 antagonist, is advancing through phase I with phase II trials planned in IBD and other autoimmune diseases. First clinical data are expected in the first half of 2026.
-
A novel DR3-targeting antibody program aims to improve IBD remission rates by leveraging unique receptor biology and overcoming immunogenicity challenges seen with TL1A antibodies. Phase one trials are imminent, with a parallel half-life extended version in development to enable less frequent dosing.
-
The presentation highlighted the scientific rationale for targeting DR3 in inflammatory bowel diseases, emphasizing its broader and more stable expression compared to TL1A. The lead DR3 antibody, SL-325, is entering clinical trials in 2024, with initial data expected by year-end and a key presentation at the European Crohn's and Colitis Congress.
Fiscal Year 2024
-
Targeting DR3 offers mechanistic and clinical advantages over TL1A, including durable receptor occupancy and potentially improved remission rates in IBD. The program is on track for IND in mid-2025, with initial clinical data expected by mid-2026.
-
The lead program SL325 targets DR3, aiming for more durable IBD inflammation control than TL1A antibodies. Preclinical and registry data support DR3 as a superior target, and clinical trials are set to begin in mid-2025, with phase II studies to follow.
-
Interim data for SL-172154 in high-risk MDS and TP53 mutant AML showed only marginal survival benefits, leading to its discontinuation. Focus shifts to SL-325, a first-in-class DR3 antagonist antibody with promising preclinical efficacy and a phase I trial planned for 2026.
-
SL172154 combined with azacitidine showed promising safety and efficacy in high-risk TP53 mutant AML and MDS, with higher complete response and MRD negativity rates than historical controls. Infusion reactions were manageable, and no significant anemia was observed.